Progress in the Application of Nanoparticles in the Prevention and Treatment of Cervical Cancer

doi:10.12280/gjfckx.20240820

Abstract

Abstract:

Cervical cancer, as a common gynecological malignant tumor, its incidence rate is increasing year by year. Traditional treatment modalities such as radiotherapy, chemotherapy, and surgery still have serious limitations. Advances in nanomedicine have brought new possibilities for the treatment of cervical cancer, especially the application of nanotechnology has become a hot research topic. Nanoparticles (NPs) have become an efficient nanocarrier system due to their excellent specific surface area and high drug loading capacity, as well as diversified material choices and good biocompatibility. NPs are not only capable of carrying a variety of therapeutic drugs, but also can realize high-dose centralized drug delivery or long-term sustained-release by accurately controlling the location and time of drug release, thus improving drug efficacy and reducing adverse effects. These advantages make NPs show great potential in enhancing drug efficacy and play a key role in new therapeutic strategies. In recent years, researchers have utilized NPs to construct a targeted delivery system for cervical cancer cells, bringing new hope to the diagnosis and treatment of cervical cancer.

Key words: Nanoparticles, Microspheres, Uterine cervical neoplasms, Drug carriers, Diagnosis, Therapy, Tumor microenvironment, Biocompatibility, Precision medicine

ZHANG Ye, CHEN Qiao-yun, ZHAO Jia-yi, CHEN Lu, LIU Jian-rong. Progress in the Application of Nanoparticles in the Prevention and Treatment of Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 8-12.

References 42

[1]	Inoue S, Ito H, Hosono S, et al. Net Survival of Elderly Patients with Gynecological Cancer Aged Over 75 Years in 2006-2008[J]. Asian Pac J Cancer Prev, 2019, 20(2):437-442. doi: 10.31557/APJCP.2019. 20.2.437.
[2]	Matsuo K, Shimada M, Yamaguchi S, et al. Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer[J]. Obstet Gynecol, 2019, 133(6):1086-1098. doi: 10.1097/AOG.0000000000003280. pmid: 31135722
[3]	Li K, Wei J, Yu H, et al. A Generic Method for Preparing Hollow Mesoporous Silica Catalytic Nanoreactors with Metal Oxide Nanoparticles inside Their Cavities[J]. Angew Chem Int Ed Engl, 2018, 57(50):16458-16463. doi: 10.1002/anie.201810777.
[4]	Yang Y, Zhang N, Jiang W. unctional DNA-Zn(2+) coordination nanospheres for sensitive imaging of 8-oxyguanine DNA glycosylase activity in living cells[J]. Talanta, 2024,280:126779. doi: 10.1016/j.talanta.2024.126779.
[5]	Cui L, Perini G, Palmieri V, et al. Plant-Derived Extracellular Vesicles as a Novel Frontier in Cancer Therapeutics[J]. Nanomaterials (Basel), 2024, 14(16):1331. doi: 10.3390/nano14161331.
[6]	Abas BI, Demirbolat GM, Cevik O. Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel[J]. PLoS One, 2022, 17(9):e0274607. doi: 10.1371/journal.pone.0274607.
[7]	Zhao B, Lin H, Jiang X, et al. Exosome-like nanoparticles derived from fruits, vegetables, and herbs: innovative strategies of therapeutic and drug delivery[J]. Theranostics, 2024, 14(12):4598-4621. doi: 10.7150/thno.97096. pmid: 39239509
[8]	Adeyemi SA, Az-Zamakhshariy Z, Choonara YE. In Vitro Prototyping of a Nano-Organogel for Thermo-Sonic Intra-Cervical Delivery of 5-Fluorouracil-Loaded Solid Lipid Nanoparticles for Cervical Cancer[J]. AAPS PharmSciTech, 2023, 24(5):123. doi: 10.1208/s12249-023-02583-y. pmid: 37226039
[9]	Almomen A, Badran M, Alhowyan AA, et al. Imiquimod-Loaded Chitosan-Decorated Di-Block and Tri-Block Polymeric Nanoparticles Loaded In Situ Gel for the Management of Cervical Cancer[J]. Gels, 2023, 9(9):713. doi: 10.3390/gels9090713.
[10]	Curro II, Teasdale CA, Wyatt LC, et al. Cancer Screening, Knowledge, and Fatalism among Chinese, Korean, and South Asian Residents of New York City[J]. Cancer Epidemiol Biomarkers Prev, 2024, 33(11):1475-1483. doi: 10.1158/1055-9965.EPI-24-0399.
[11]	Liu S, Xu T, Chen X, et al. TP53AIP1 induce autophagy via the AKT/mTOR signaling pathway in the breast cancer cells[J]. Cancer Biol Ther, 2024, 25(1):2398297. doi: 10.1080/15384047.2024.2398297.
[12]	Jacquin E, Saunier M, Lepiller Q, et al. The level of expression of HPV16 early transcripts is not associated with the natural history of cervical lesions[J]. J Med Virol, 2024, 96(9):e29875. doi: 10.1002/jmv.29875.
[13]	Luo Y, Niu M, Liu Y, et al. Oncoproteins E6 and E7 upregulate topoisomerase I to activate the cGAS-PD-L1 pathway in cervical cancer development[J]. Front Pharmacol, 2024,15:1450875. doi: 10.3389/fphar.2024.1450875.
[14]	Neupane KR, Aryal SP, Harvey BT, et al. Organelle Specific Macrophage Engineered Vesicles Differentially Reprogram Macrophage Polarization[J]. Adv Healthc Mater, 2024, 13(30):e2401906. doi: 10.1002/adhm.202401906.
[15]	Yin P, Sun D, Deng Y, et al. Metal-organic cage as a theranostic nanoplatform for magnetic resonance imaging guided chemodynamic therapy[J]. Theranostics, 2024, 14(12):4861-4873. doi: 10.7150/thno.97264. pmid: 39239515
[16]	Dover L, Dulaney C. PROshot: Immunotherapy for Cervical Cancer, Epidermal Growth Factor Receptor-Mutated Stage Ⅲ Lung Cancer, Perioperative Chemotherapy for Esophageal Cancer, Salvage Postprostatectomy Radiation and Androgen Deprivation Therapy, and Immunotherapy for Head and Neck Cancer[J]. Pract Radiat Oncol, 2024, 14(5):363-367. doi: 10.1016/j.prro.2024.06.001.
[17]	Gao H, Wu H, Zhang Y, et al. Long-term survival in patients with para-aortic metastatic cervical cancer receiving simultaneous integrated boost chemoradiation to positive lymph nodes: a single-center experience[J]. Int J Gynecol Cancer, 2024, 34(10):1536-1546. doi: 10.1136/ijgc-2024-005664.
[18]	Tao H, Chen Z, Yao B, et al. Galaxamide alleviates cisplatin-induced premature ovarian insufficiency via the PI3K signaling pathway in HeLa tumor-bearing mice[J]. BMC Cancer, 2024, 24(1):1060. doi: 10.1186/s12885-024-12848-9. pmid: 39192214
[19]	Yadav N, Tripathi AK, Parveen A, et al. PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression[J]. Pharmaceutics, 2022, 14(7):1326. doi: 10.3390/pharmaceutics14071326.
[20]	Wang Y, Shen N, Li S, et al. Synergistic Therapy for Cervical Cancer by Codelivery of Cisplatin and JQ1 Inhibiting Plk1-Mutant Trp53 Axis[J]. Nano Lett, 2021, 21(6):2412-2421. doi: 10.1021/acs.nanolett.0c04402. pmid: 33705152
[21]	Rehman S, Alahmari F, Aldossary L, et al. Nano-sized warriors: zinc chromium vanadate nanoparticles as a dual solution for eradicating waterborne enterobacteriaceae and fighting cancer[J]. Front Pharmacol, 2023,14:1213824. doi: 10.3389/fphar.2023.1213824.
[22]	Shao S, A Ortega-Rivera O, Ray S, et al. A Scalable Manufacturing Approach to Single Dose Vaccination against HPV[J]. Vaccines (Basel), 2021, 9(1):66. doi: 10.3390/vaccines9010066.
[23]	Kim Y, Kang E. A graphitic nano-onion/molybdenum disulfide nanosheet composite as a platform for HPV-associated cancer-detecting DNA biosensors[J]. J Nanobiotechnology, 2023, 21(1):187. doi: 10.1186/s12951-023-01948-6.
[24]	Rawat R, Roy S, Goswami T, et al. An Electroanalytical Flexible Biosensor Based on Reduced Graphene Oxide-DNA Hybrids for the Early Detection of Human Papillomavirus-16[J]. Diagnostics (Basel), 2022, 12(9):2087. doi: 10.3390/diagnostics12092087.
[25]	Pareek S, Jain U, Bharadwaj M, et al. An ultrasensitive electrochemical DNA biosensor for monitoring Human papillomavirus-16 (HPV-16) using graphene oxide/Ag/Au nano-biohybrids[J]. Anal Biochem, 2023,663:115015. doi: 10.1016/j.ab.2022.115015.
[26]	Appidi T, Vakada M, Buddhiraju HS, et al. Development of a Point-of-Care Cervico-Vaginal Sampling/Testing Device for the Colorimetric Detection of Cervical Cancer[J]. Diagnostics (Basel), 2023, 13(8):1382. doi: 10.3390/diagnostics13081382.
[27]	Jin J, Liu Z, Chen Y. Effect of Nano-Tracer on Identification of Sentinel Lymph Nodes in Pelvic Cavity and Postoperative Complications in Patients with Cervical Cancer[J]. J Nanosci Nanotechnol, 2021, 21(2):971-976. doi: 10.1166/jnn.2021.18706. pmid: 33183432
[28]	Liu L, Lei H, Hou G, et al. Gas-Amplified Metalloimmunotherapy with Dual Activation of Pyroptosis and the STING Pathway for Remodeling the Immunosuppressive Cervical Cancer Microenvironment[J]. ACS Nano, 2024, 18(20):12830-12844. doi: 10.1021/acsnano.4c00017. pmid: 38709246
[29]	Mohapatra A, Rajendrakumar SK, Cherukula K, et al. A sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer[J]. Biomater Sci, 2023, 11(5):1853-1866. doi: 10.1039/d2bm01715f.
[30]	Qi L, Pan T, Ou L, et al. Biocompatible nucleus-targeted graphene quantum dots for selective killing of cancer cells via DNA damage[J]. Commun Biol, 2021, 4(1):214. doi: 10.1038/s42003-021-01713-1. pmid: 33594275
[31]	Fathy MM, Elfiky AA, Bashandy YS, et al. An insight into synthesis and antitumor activity of citrate and gallate stabilizing gold nanospheres[J]. Sci Rep, 2023, 13(1):2749. doi: 10.1038/s41598-023-29821-4. pmid: 36797452
[32]	Karthikeyan C, Varaprasad K, Venugopal SK, et al. Biocidal (bacterial and cancer cells) activities of chitosan/CuO nanomaterial, synthesized via a green process[J]. Carbohydr Polym, 2021,259:117762. doi: 10.1016/j.carbpol.2021.117762.
[33]	Fu Y, Zhang Y, Zhang Y, et al. Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells[J]. ACS Appl Mater Interfaces, 2024, 16(37):49053-49068. doi: 10.1021/acsami.4c09830.
[34]	Wu L, Tan Y, Zhang H, et al. A laser free self-luminous nanosystem for photodynamic therapy of cervical cancer cells[J]. Photodiagnosis Photodyn Ther, 2023,44:103756. doi: 10.1016/j.pdpdt.2023.103756.
[35]	Garg P, Ramisetty SK, Raghu Subbalakshmi A, et al. Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential[J]. Biochem Pharmacol, 2024,229:116498. doi: 10.1016/j.bcp.2024.116498.
[36]	Li M, Wang Y, Zhang L, et al. Cancer Cell Membrane-Enveloped Dexamethasone Normalizes the Tumor Microenvironment and Enhances Gynecologic Cancer Chemotherapy[J]. ACS Nano, 2023, 17(17):16703-16714. doi: 10.1021/acsnano.3c03013.
[37]	Kumari S, Nehra A, Gupta K, et al. Chlorambucil-Loaded Graphene-Oxide-Based Nano-Vesicles for Cancer Therapy[J]. Pharmaceutics, 2023, 15(2):649. doi: 10.3390/pharmaceutics15020649.
[38]	Kalogera E, Nevala WK, Finnes HD, et al. A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies[J]. Clin Cancer Res, 2024, 30(12):2623-2635. doi: 10.1158/1078-0432.CCR-23-3196.
[39]	Jagaran K, Singh M. Copolymer-Green-Synthesized Copper Oxide Nanoparticles Enhance Folate-Targeting in Cervical Cancer Cells In Vitro[J]. Polymers (Basel), 2023, 15(10):2393. doi: 10.3390/polym 15102393.
[40]	Venkatas J, Singh M. Curcumin-reduced gold nanoparticles facilitate IL-12 delivery to a cervical cancer in vitro cell model[J]. Nanomedicine (Lond), 2023, 18(13):945-960. doi: 10.2217/nnm-2023-0076.
[41]	Shariare MH, Khan MA, Al-Masum A, et al. Development of Stable Liposomal Drug Delivery System of Thymoquinone and Its In Vitro Anticancer Studies Using Breast Cancer and Cervical Cancer Cell Lines[J]. Molecules, 2022, 27(19):6744. doi: 10.3390/molecules27196744.
[42]	Sundara Rajan RS, Thomas J, Francis D, et al. Effective gene delivery using size dependant nano core-shell in human cervical cancer cell lines by magnetofection[J]. PLoS One, 2023, 18(9):e0289731. doi: 10.1371/journal.pone.0289731.